Correction: Combined MEK and ERK inhibition overcomes therapy-mediated pathway reactivation in RAS mutant tumors.

Merchant, Mark; Moffat, John; Schaefer, Gabriele; Chan, Jocelyn; Wang, Xi; Orr, Christine; Cheng, Jason; Hunsaker, Thomas et al. · PLoS One · 2018

Where this comes from

Record sourced from PubMed, PMID 29370292.
Also identified by DOI 10.1371/journal.pone.0192059 and PMC identifier 5785022.
No licence information is recorded for this record.
Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0185862.].

Read the full text

View on PubMed · Publisher (DOI)